• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is TransMedics Group (TMDX) Undervalued Following Its Earnings Miss And Margin Guidance Cut?

    Simply Wall St·09/04/2026 00:30:06
    Listen to the news

    TransMedics Group earnings miss and guidance update put renewed focus on growth spending

    TransMedics Group (TMDX) recently reported second quarter 2026 earnings per share of $0.44, missing estimates. At the same time, the company raised the lower end of its 2026 revenue outlook while cutting adjusted operating margin guidance.

    The updated outlook now points to expected revenue growth of about 22% to 25% for 2026. Management tied the reduced margin guidance to higher spending on OCS Kidney development, clinical programs and international expansion, which are increasingly important to the overall TransMedics Group story.

    At a share price of $86.98, TransMedics Group has seen a 25.28% 90-day share price return and a 7.72% 30-day share price return, although the share price is down 29.11% year to date and the 1-year total shareholder return is down 16.41%. At the same time, the 5-year total shareholder return of 170.97% and 3-year total shareholder return of 37.67% underline how investors have previously been willing to back the long-term growth story, even through periods where sentiment softens around higher spending and earnings misses.

    Spot under-the-radar compounders facing similar growth investment trade offs by scanning our hand picked 21 high quality undiscovered gems alongside TransMedics Group.

    For TransMedics Group, the recent pullback sits against a longer record of shareholder gains and ongoing growth spending. Are you seeing a business that has changed, or sentiment resetting around the same transplant platform story as before?

    Most Popular Narrative: 10.6% Undervalued

    TransMedics Group's most followed narrative points to a fair value of $97.30, which sits above the recent close at $86.98 and frames the current pullback as a valuation gap based on long term transplant and logistics growth assumptions.

    International geographic expansion, especially the planned replication of the U.S. NOP model in Europe (representing 45% of global transplant volumes), could nearly double the company's total addressable market, increasing both top-line revenue potential and the ability to achieve greater operating leverage.

    Read the complete narrative.

    Want to see what has to go right for that fair value to hold up? The narrative focuses on rising transplant volumes, higher margin services and a richer product mix. The key question is how those moving parts are expected to shape future revenue, earnings and valuation multiples over the next few years.

    Result: Fair Value of $97.30 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, TransMedics Group still faces meaningful risks, including regulatory scrutiny on organ procurement practices and potential competitive pressure that could affect procedure volumes and pricing power.

    Find out about the key risks to this TransMedics Group narrative.

    Next Steps

    Given the mixed mood around TransMedics Group today, it could be useful to act promptly and review the underlying data for yourself. Start by weighing the 4 key rewards

    Looking for more investment ideas beyond TransMedics Group?

    If you stop with TransMedics Group, you could miss other opportunities that match your style. Use the Simply Wall St Screener to surface ideas tailored to you.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.